Loading...
PHAR logo

Pharming Group N.V.NasdaqGM:PHAR Stock Report

Market Cap US$892.7m
Share Price
US$12.59
US$27.12
53.6% undervalued intrinsic discount
1Y9.3%
7D2.5%
1D
Portfolio Value
​
View

Pharming Group N.V.

NasdaqGM:PHAR Stock Report

Market Cap: US$892.7m

Pharming Group (PHAR) Stock Overview

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. More details

PHAR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 78% below our estimate of its fair value

Earnings are forecast to grow 28.18% per year

Became profitable this year

Risk Analysis

Large one-off items impacting financial results


PHAR Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Pharming Group N.V. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pharming Group
Historical stock prices
Current Share Price€12.59
52 Week High€21.34
52 Week Low€9.54
Beta0.098
1 Month Change-3.00%
3 Month Change-20.72%
1 Year Change9.29%
3 Year Change-1.25%
5 Year Change3.62%
Change since IPO-24.61%

Recent News & Updates

Recent updates

Seeking Alpha • Feb 04

Pharming Group: Crossing From Speculation To Profitability

Summary Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company. PHAR delivered $376M in FY2025 revenue, up 27% YoY, surpassing guidance, and generated $44M in operating cash flow, supporting financial independence. Key near-term catalysts include FDA approval for Joenja's pediatric label and pivotal data from leniolisib and KL1333 clinical programs. The company's commercial infrastructure and pipeline expansion position it for significant upside as rare disease market opportunities broaden. Read the full article on Seeking Alpha
Seeking Alpha • Apr 01

Pharming Group: Small Dutch Company With Strong Revenues

Summary Pharming Group, a Dutch biotech firm, excels with RUCONEST and JOENJA, showing strong revenue growth and positive cash flow despite low US trading volume. RUCONEST and JOENJA drive revenue, with RUCONEST contributing $252.2M and JOENJA surging 147% to $45M in its first full year. Acquired KL1333, a promising late-stage molecule for mitochondrial diseases, enhancing their pipeline and expanding market potential. Despite low US trading volume, Pharming Group's robust financials and growth prospects make it a compelling investment for those with access to Euronext. Read the full article on Seeking Alpha
Seeking Alpha • Sep 28

Pharming's rare immunodeficiency disorder drug gets FDA priority review

The U.S. Food and Drug Administration ((FDA) granted priority review to Pharming (NASDAQ:PHAR) application seeking approval of oral drug leniolisib to treat the rare primary immunodeficiency activated phosphoinositide 3-kinase delta syndrome (APDS) in patients 12 years of age and older in the U.S. The FDA accepted the company's New Drug Application (NDA) and is expected to make a decision by March 29, 2023. Under priority review, the FDA's goal is to take action within six months, compared to 10 months under standard review. The NDA was backed by data from a phase 2/3 study of leniolisib, which met its co-primary goals of reduction in index lymph node size and correction of immunodeficiency, the Netherlands-based company said in a Sept. 28 press release. APDS is a rare immunodeficiency disease that affects 1 to 2 people per million and is caused by variants in either of two genes, PIK3CD or PIK3R1, that regulate maturation of white blood cells, according to the company.
Seeking Alpha • Aug 01

Pharming gets EMA panel nod for accelerated review of leniolisib for rare immunodeficiency disorder

A committee of the European Medicines Agency (EMA) granted accelerated assessment for Pharming's (NASDAQ:PHAR) potential application seeking approval of leniolisib to treat patients aged 12 years and older with activated phosphoinositide 3-kinase (PI3K) delta syndrome (APDS). The company said it plans to submit the marketing authorization application (MAA) to the EMA in October. Pharming noted that an accelerated assessment reduces the timeframe for review by the EMA's Committee for Medicinal Products for Human Use (CHMP) to 150 days from 210 days. The company said clinical development for leniolisib includes positive data from a phase 2/3 trial. APDS is a rare immunodeficiency disease that affects 1 to 2 people per million and is caused by variants in either of two genes, PIK3CD or PIK3R1, that regulate maturation of white blood cells, the company said in an Aug. 1 press release.

Shareholder Returns

PHARUS BiotechsUS Market
7D2.5%2.1%-3.3%
1Y9.3%25.0%22.3%

Return vs Industry: PHAR underperformed the US Biotechs industry which returned 24.3% over the past year.

Return vs Market: PHAR underperformed the US Market which returned 22.5% over the past year.

Price Volatility

Is PHAR's price volatile compared to industry and market?
PHAR volatility
PHAR Average Weekly Movement9.9%
Biotechs Industry Average Movement10.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: PHAR has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: PHAR's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1988407Fabrice Chouraquiwww.pharming.com

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group N.V. Fundamentals Summary

How do Pharming Group's earnings and revenue compare to its market cap?
PHAR fundamental statistics
Market capUS$892.70m
Earnings (TTM)US$12.36m
Revenue (TTM)US$369.49m
72.2x
P/E Ratio
2.4x
P/S Ratio

Is PHAR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHAR income statement (TTM)
RevenueUS$369.49m
Cost of RevenueUS$43.82m
Gross ProfitUS$325.67m
Other ExpensesUS$313.31m
EarningsUS$12.36m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Jul 30, 2026

Earnings per share (EPS)0.017
Gross Margin88.14%
Net Profit Margin3.34%
Debt/Equity Ratio36.7%

How did PHAR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 00:50
End of Day Share Price 2026/06/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharming Group N.V. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Whitney IjemCanaccord Genuity
John SavinEdison Investment Research
Simon ScholesFirst Berlin Equity Research GmbH